NEWAMSTERDAM PHARMA CO NV (NAMS)
NL00150012L7 - Common Stock
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
The company's combination treatment lowered LDL cholesterol by about 50% over 84 days.
Which stocks are moving before the opening bell on Wednesday?
Stay updated with the stocks that are on the move in Wednesday's pre-market session.
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9%...
Bullish Two Hundred Day Moving Average Cross - NAMS
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
– Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma Breaks Above 200-Day Moving Average - Bullish for NAMS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Oct. 04, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, Sept. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the...
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
-- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved primary endpoint of LS mean...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Aug. 02, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
Menarini gibt positive Ergebnisse der Phase-3-Zulassungsstudie BROOKLYN bekannt, die die Wirksamkeit, Sicherheit und Verträglichkeit von Obicetrapib bei Patienten mit heterozygoter familiärer Hypercholesterinämie untersucht
/PRNewswire/ -- Die Menarini Group gibt heute positive Topline-Daten aus der klinischen Phase-3-Studie BROOKLYN (NCT05425745) bekannt, die von NewAmsterdam...
Menarini annonce des données de base positives de l'essai clinique pivot de phase 3 BROOKLYN évaluant l'efficacité, l'innocuité et la tolérance de l'Obicetrapib chez des patients atteints d'hypercholestérolémie familiale hétérozygote.
-- Atteint le critère principal de réduction moyenne de moindre carré du LDL-C en plus des thérapies de modification des lipides aux doses maximales tolérées à...
Oversold Conditions For NewAmsterdam Pharma (NAMS)
NewAmsterdam Pharma (NAMS) Shares Cross Below 200 DMA
Menarini anuncia datos positivos del ensayo clínico fundamental de fase 3 BROOKLYN
-Menarini anuncia datos positivos del ensayo clínico fundamental de fase 3 BROOKLYN que evalúa la eficacia, seguridad y tolerabilidad de obicetrapib en...
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
/PRNewswire/ -- Menarini Group today announces positive topline data from the Phase 3 BROOKLYN clinical trial (NCT05425745) sponsored by NewAmsterdam Pharma...
NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
The company is hoping to use a new mechanism to lower "bad" LDL cholesterol.
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
Company to host conference call on Monday, July 29 at 8:30 a.m. ET
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
Company to host conference call on Monday, July 29 at 8:30 a.m. ET...
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
-- Company expects to report topline data in the first quarter of 2025 --...